Biotech
Aug. 11, 2011
David M. Hoffmeister
The potential loss of lives, along with jobs, has Hoffmeister concerned about the U.S. Food and Drug Administration's increasingly hard-line approach to moving new products through the pipeline.
"The FDA has certainly tightened up the screws on small medical device companies and pharmaceuticals in what it takes to get products on the market," he said.
Time being money, this is costing companies megamillions, Hoffmeister said. <...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In